The cervical cancer diagnostics market is projected to grow from USD 4.4 billion in 2025 to USD 7.1 billion by 2034 at a CAGR of ~5%. Growth is driven by rising cervical cancer prevalence, increasing adoption of advanced diagnostic technologies like HPV testing and AI-powered screening tools, government screening initiatives, and expanding healthcare infrastructure particularly in emerging economies. North America leads the market with 44% share in 2025.

The cancer biomarkers market is projected to grow from USD 23.22 billion in 2026 to USD 35.16 billion by 2031, with a CAGR of 8.65%. Growth is driven by increasing cancer prevalence, rising adoption of personalized medicine, advancements in molecular diagnostics, and expanding use of companion diagnostics. North America leads the market while Asia-Pacific emerges as a high-growth region.

The AI in life sciences market is projected to grow from USD 2.2 billion in 2025 to USD 11.5 billion by 2034, driven by accelerated drug discovery, precision medicine adoption, and increasing healthcare data availability. North America leads with 44.78% market share, while Europe and Asia-Pacific show significant growth potential. Major pharmaceutical and technology companies are investing heavily through partnerships and AI-enabled platforms.

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

The personalized medicine market is projected to grow from USD 524 billion in 2025 to USD 1 trillion by 2034, driven by advances in genomics, AI-powered diagnostics, and targeted therapies. North America leads the market with 41% share, while Asia-Pacific emerges as a key growth engine. Major pharmaceutical and biotech companies are investing heavily in precision medicine solutions across oncology, rare diseases, and chronic conditions.

The global DNA microarray market is expected to grow from USD 2.5 billion in 2025 to USD 4.7 billion by 2034 at a CAGR of ~7%. Growth is driven by rising demand for genomic research, personalized medicine, early disease diagnosis, and increasing prevalence of cancer and genetic disorders. North America leads the market with 41.39% share, while Asia-Pacific emerges as a key growth contributor.

The global Targeted DNA RNA Sequencing Market was valued at USD 8.6 billion in 2025 and is projected to reach USD 46.9 billion by 2035, growing at an 18.5% CAGR. Growth is driven by government genomic surveillance initiatives, pharmaceutical biomarker discovery, and rising demand for precision medicine. North America leads in market share while Asia Pacific shows the highest growth rate.

The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.

Metafoodx, an AI-powered kitchen intelligence platform, will showcase its 3D AI food tracking technology at the 2026 National Restaurant Association Show in Chicago. The platform uses AI scanning to capture food production data in real-time, helping operators reduce waste by up to 90% and achieve 500x ROI. The company is launching new features including an enhanced AI Weekly Report and Catering Mode to optimize kitchen operations and reduce overproduction.

President Trump signed S. 3971, reauthorizing the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs through 2031. The legislation includes reforms to strengthen national security, accountability, and innovation. Since 1982, these programs have invested over $81 billion into 34,000+ small businesses and supported major companies including Anduril, Qualcomm, Biogen, Illumina, and iRobot.

The global NGS market is projected to reach USD 29.53 billion by 2030 from USD 14.94 billion in 2025, growing at a CAGR of 14.6%. Growth is driven by expanding applications in oncology, infectious diseases, and precision medicine, with Asia-Pacific exhibiting the fastest regional growth. Consumables dominate the product segment, while academic and research institutes lead the services end-user segment.

The global DNA read, write and edit market is projected to grow from $21.4 billion in 2024 to $67.7 billion by 2030 at a 21.2% CAGR, driven by expanding clinical applications of genome editing, genomic diagnostics demand, and CRISPR-based therapeutics investment. North America leads with 43.5% market share.